Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Asset Writedowns and Impairment (2023 - 2025)

Maxcyte (MXCT) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with -$136000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 114.11% to -$136000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $966000.0, a 23.21% increase, with the full-year FY2024 number at $1.8 million, up 935.67% from a year prior.
  • Asset Writedowns and Impairment was -$136000.0 for Q3 2025 at Maxcyte, down from $100000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $964000.0 in Q3 2024 to a low of -$260000.0 in Q2 2024.
  • A 3-year average of $193444.4 and a median of $65000.0 in 2025 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 10811.11% in 2024, then crashed 114.11% in 2025.
  • Maxcyte's Asset Writedowns and Impairment stood at -$50000.0 in 2023, then skyrocketed by 1974.0% to $937000.0 in 2024, then plummeted by 114.51% to -$136000.0 in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Asset Writedowns and Impairment are -$136000.0 (Q3 2025), $100000.0 (Q2 2025), and $65000.0 (Q1 2025).